Eye pressure check after Eylea 8mg injection
Part of Eyes & vision clinical trials.
This trial measures eye pressure right after an injection of a higher-dose Eylea (aflibercept 8mg) to see how it affects the eye. It may help people who need frequent anti-VEGF shots for conditions like wet AMD or diabetic eye disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your doctor has prescribed Eylea 8mg for your eye condition
- You are either starting Eylea for the first time or switching from another anti-VEGF treatment because you are not responding well enough
- You have health insurance (social security coverage)
- You are not pregnant or breastfeeding
- You are not under legal guardianship or similar protection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This study tests a higher dose of the medicine aflibercept (brand name Eylea) in people who have already had at least three eye injections for wet age-related macular degeneration or diabetic macular edema. The goal is to see how well this stronger dose works in real-life conditions and how long its effects last.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This trial tests a new injection medicine (AIV007) placed around the eye to treat wet age-related macular degeneration (a condition that damages central vision). You may qualify if you've been treated for this condition before and responded well to previous eye injections.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
Hear when a new Macular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.